SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Therapeutics, Inc. (Nasdaq: MBRX - News) announced today that an article describing the glucose lowering activity of CS-917 in animal models of type 2 diabetes was published in the June 2006 issue of Diabetes. The article, entitled “Inhibition of Fructose 1,6-Bisphosphatase (FBPase) Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats” discusses the efficacy and safety profile of the lead compound, CS-917, in animal models of early- and late-stage diabetes. CS-917 is a first-in-class oral product candidate discovered by Metabasis using its proprietary NuMimetic(TM) technology that is currently being studied in a Phase IIb human clinical trial for type 2 diabetes. CS-917 is being developed in partnership with Daiichi Sankyo.
